BridgeMD
Cluster randomised trial of blood thinners
EU CTIS ID: 2022-502402-32-00
What this study is testing
To evaluate whether treatment with any of the low molecular weight heparins will increase the risk of bleeding requiring bleeding during admission or death within 30 days in patients with indication for low molecular weight heparins, compared with one of the other low molecular weight heparins
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients that will be included in the study will be patients that are admitted to the hospital and who has indication for treatment with a low molecular weight heparin. Patients will only be included the first time they are admitted in the period the study run.
You likely can't join if
- • Patients under the age of 18 • Patients that incapable of understanding the written material received • Patients that after being informed in writing choses not participate
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.